Symbravo (AXS-07)
Migraine
ApprovedCommercial
Key Facts
About Axsome Therapeutics
Axsome Therapeutics is a commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for central nervous system (CNS) disorders. Founded in 2012, the company has transitioned from a development-focused entity to a revenue-generating commercial organization with three FDA-approved products: Auvelity (AXS-05) for MDD, Sunosi for narcolepsy/OSA, and Symbravo for migraine. Its core strategy leverages a differentiated platform focused on synergistic drug combinations and novel formulations to address significant unmet needs in psychiatry, neurology, and pain, driving a market valuation exceeding $8 billion.
View full company profileTherapeutic Areas
Other Migraine Drugs
| Drug | Company | Phase |
|---|---|---|
| Migraine Clinical Trials | DM Clinical Research | Not Specified |
| Sumatriptan Alginate Film | Klaria | Not Specified (Clinical) |
| DerMap™ Platform | ArrayPatch | Research |
| MST-02 | Miist Therapeutics | Preclinical |
| Relonova (Rizatriptan) | NovaMedica | Approved |
| EVO756 | Evommune | Phase 1 |